Zura Bio announced Q3 financial results and confirmed key trial milestones. With $187.7 million in cash, the company expects to fund operations through 2028 as it awaits topline data for its TibuSHIELD and TibuSURE studies.
Zura Bio announced Q3 financial results and confirmed key trial milestones. With $187.7 million in cash, the company expects to fund operations through 2028 as it awaits topline data for its TibuSHIELD and TibuSURE studies.